Category: basic life sciences retractions

Surgery chair who blamed image issues on software logs three more retractions

A researcher who claimed image problems in a retracted paper were the result of a software glitch, and not intentional, has lost three more papers — all for image manipulation.

In two notices, the Journal of Biological Chemistry specifies that duplicated images were used to represent different experimental conditions; one notice simply says the paper was affected by image manipulation.

All of the notices specify the papers are being retracted by the publisher, the American Society for Biochemistry and Molecular Biology — which this month published a set of recommendations for preparing a paper, including how to avoid excessive manipulation.

The papers were published between 2002 and 2010, and all share the same last author (Paul Kuo, currently chair of surgery at Loyola Medicine) and first author (Hongtao Guo, at Duke).

Here’s the first notice:

Continue reading Surgery chair who blamed image issues on software logs three more retractions

“We made big mistakes:” Gastric paper pulled with unusual notice

Sometimes we come across a real head-scratcher.

That happened this week, when we saw a retraction notice for a 2015 paper on gastric cancer in the International Journal of Clinical and Experimental Medicine, which only says the authors “made big mistakes” and contains two fairly significant typos.

Although there’s no sign of a retraction on PubMed, the table of contents for the latest issue of the journal lists the retraction — but includes no hyperlink to the notice. The only way to see it is via a Web cached version. Here’s the text:

Continue reading “We made big mistakes:” Gastric paper pulled with unusual notice

What turned a cancer researcher into a literature watchdog?

Jennifer Byrne

Sometime in the middle of 2015, Jennifer Byrne, professor of molecular oncology at the University of Sydney, began her journey from cancer researcher to a scientific literature sleuth, seeking out potentially problematic papers.

The first step was when she noticed several papers that contained a mistake in a DNA construct which, she believed, meant the papers were not testing the gene in question, associated with multiple cancer types.  She started a writing campaign to the journal editors and researchers, with mixed success. But less than two years later, two of the five papers she flagged have already been retracted.

When asked why she spent time away from bench research to examine this issue, Byrne told us:  Continue reading What turned a cancer researcher into a literature watchdog?

A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.

How did this happen? Continue reading A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

At last, cancer reproducibility project releases some results — and they’re mixed

Nearly five years ago, researchers suggested that the vast majority of preclinical cancer research wouldn’t hold up to follow-up experiments, delaying much needed treatments for patients. In a series of articles publishing tomorrow morning, eLife has released the results of the first five attempts to replicate experiments in cancer biology — and the results are decidedly mixed.

As our co-founders Adam Marcus and Ivan Oransky write in STAT, the overall take-home message was that two studies generated findings similar to the original, one did not replicate the original, and two others were inconclusive.

They quote Brian Nosek, a psychologist at the University of Virginia, in Charlottesville, who runs the Center for Open Science, who has been leading the replication effort in his own field:

Continue reading At last, cancer reproducibility project releases some results — and they’re mixed

Breast cancer studies by fired Pfizer employee retracted

Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.

One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.

Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Continue reading Breast cancer studies by fired Pfizer employee retracted

“Crucial experiments” missing from retracted plant study

A 2016 study was retracted from a Frontiers journal after editors realized the authors had omitted experiments that didn’t support the hypothesis. 

Gearóid Ó Faoleán, ethics and integrity manager at Frontiers, which publishes Frontiers in Plant Science, told us:

In accordance with our complaints protocol, the Field Chief Editor led the investigation that resulted in the decision to retract the paper.

Here’s the retraction notice: Continue reading “Crucial experiments” missing from retracted plant study

Authors retract two statin papers, one with problems “too extensive to revise”

Researchers in China have retracted two 2016 papers about the possible use of a cholesterol-lowering agent to treat bleeding on the brain.

One of the retracted papers in the Journal of Neurosurgery (JNS) had multiple problems that were “too extensive to revise,” according to the lengthy retraction notice, relating to issues with authorship, data analyses, and patient enrollment. The notice is signed by first author Hua Liu of the Nanjing Medical University in China.

Liu is also the first author of another recently retracted paper in Frontiers in Neuroscience, pulled for incorrectly categorizing patients.

The JNS retraction notice begins: Continue reading Authors retract two statin papers, one with problems “too extensive to revise”

Journal retracts gastric cancer study with multiple duplications, authors MIA

An oncology journal has decided to retract a 2012 paper on gastric cancer after discovering duplicated data in multiple figures.

According to the retraction notice, the journal’s editorial board received a tip from a reader regarding the potential figure issues. Oncology Reports launched an investigation, which confirmed the allegations. The authors failed to respond to the journal’s multiple requests for more information.

Here’s the retraction notice: Continue reading Journal retracts gastric cancer study with multiple duplications, authors MIA

Nature paper with massive correction can’t be reproduced, says independent group

In 2011, authors of a Nature letter caught some flak for issuing a lengthy correction to a neuroscience paper that had raised eyebrows within days of publication — including some suggestions it should be retracted.

The correction notice, published months after the original letter, cited errors in image choice and labeling, but asserted the conclusions remained valid.

Now, those conclusions appear up for debate. In a recent Nature Brief Communications Arising (BCA) article, a team that raised concerns about the paper five years ago says they are unable to reproduce the results. But the authors of the original paper aren’t convinced: They argue that the BCA fails to cite important evidence, has a “complete absence or low quality of analysis,” and the scientists disregard some of their data.

Continue reading Nature paper with massive correction can’t be reproduced, says independent group